Obinutuzumab Biosimilar, CD20 Monoclonal Antibody

Obinutuzumab Biosimilar uses the same protein sequences as the therapeutic antibody obinutuzumab. Obinutuzumab is an antineoplastic CD20 antibody used to treat untreated chronic lymphocytic leukemia in combination with chlorambucil. In contrast to rituximab, which is a classic type I CD20 antibody, obinutuzumab binds to type II CD20 antibodies. This allows obinutuzumab to have a much higher induction of antibody-dependant cytotoxicity and a higher direct cytotoxic effect than the classic CD20 antibodies.

Product Details
Species Reactivity	Human
Source	The obinutuzumab biosimilar CHO stable cell line
Host/Isotype	Human IgG1 kappa
Class	Monoclonal
Type	Antibody
Immunogen	The human type II CD20 antibodies
Clone	Obinutuzumab Biosimilar
Conjugate	Unconjugated
Purity	>95%
Molecular Weight	146.32 kDa
Protein Concentration	1 mg/ml
Formulation	Liquid
Storage Condition	4°C for short time, -20°C or -80°C for long time.
Storage Buffer	0.2 uM filtered PBS solution, pH 6.0